Author

J. Cassataro

Primary ORCID profile (0000-0002-7122-869X · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

J. CassataroiD1 paper

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. J. Auguste· 2 shared C. Pueblas Castro· 2 shared D. E. Alvarez· 2 shared E. F. Castro· 2 shared K. A. Pasquevich· 2 shared L. A. Bruno· 2 shared L. M. Coria· 2 shared L. M. Saposnik· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. J. Auguste

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Gamma-adapted recombinant subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection.

L. M. Coria, J. M. Rodriguez, A. Demaria, L. A. Bruno, M. Rios Medrano, C. Pueblas Castro, E. F. Castro, S. A. Del Priore, A. C. Hernando Insua, I. G. Kaufmann, L. M. Saposnik, W. B. Stone, L. Prado, V. Krum, F. M. Zurvarra, , J. Cassataro

This paper develops a Gamma-adapted subunit vaccine that induces broad neutralizing antibodies and protects mice against SARS-CoV-2 variants, including Omicron.

bioRxiv · Jan 3, 2023Immunology

A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection.

L. M. Coria, L. M. Saposnik, C. Pueblas Castro, E. F. Castro, L. A. Bruno, W. B. Stone, P. S. Perez, M. L. Darriba, L. B. Chemes, J. Alcain, I. Mazzitelli, A. Varese, M. Salvatori, A. J. Auguste, D. E. Alvarez, , J. Cassataro

This paper evaluates RBD-based vaccine formulations with different adjuvants, finding that U-Omp19+Alum significantly increases neutralizing antibodies, B cells, and provides protection against SARS-CoV-2.

bioRxiv · Dec 7, 2021 · PreprintImmunology